Revenio Group Oyj
Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally. The company offers iCare IC100, ST500, and IC200 tonometers; iCare HOME2, a tonometer to measure eye pressure; iCare Probes that are accessories of iCare tonometer for measuring intraocular pre… Read more
Revenio Group Oyj (REVXF) - Net Assets
Latest net assets as of December 2025: $114.70 Million USD
Based on the latest financial reports, Revenio Group Oyj (REVXF) has net assets worth $114.70 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($150.60 Million) and total liabilities ($35.90 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $114.70 Million |
| % of Total Assets | 76.16% |
| Annual Growth Rate | 10.47% |
| 5-Year Change | 46.25% |
| 10-Year Change | N/A |
| Growth Volatility | 3.38 |
Revenio Group Oyj - Net Assets Trend (2020–2025)
This chart illustrates how Revenio Group Oyj's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Revenio Group Oyj (2020–2025)
The table below shows the annual net assets of Revenio Group Oyj from 2020 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $114.70 Million | +6.50% |
| 2024-12-31 | $107.70 Million | +7.81% |
| 2023-12-31 | $99.89 Million | +9.87% |
| 2022-12-31 | $90.92 Million | +15.92% |
| 2021-12-31 | $78.43 Million | +12.51% |
| 2020-12-31 | $69.71 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Revenio Group Oyj's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 325.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $59.40 Million | 51.79% |
| Other Components | $55.30 Million | 48.21% |
| Total Equity | $114.70 Million | 100.00% |
Revenio Group Oyj Competitors by Market Cap
The table below lists competitors of Revenio Group Oyj ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Santacruz Silv
V:SCZ
|
$701.67 Million |
|
Shenzhen Chuangyitong Technology Co.Ltd.
SHE:300991
|
$701.67 Million |
|
Baticim Bati Anadolu Cimento Sanayi AS
IS:BTCIM
|
$701.78 Million |
|
Hainan Haiyao Co Ltd
SHE:000566
|
$702.18 Million |
|
Anant Raj Limited
NSE:ANANTRAJ
|
$701.37 Million |
|
Icade SA
PINK:CDMGF
|
$700.47 Million |
|
San Miguel AG
BA:SAMI
|
$700.38 Million |
|
Shanghai Smith Adhesive New
SHG:603683
|
$700.16 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Revenio Group Oyj's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 107,700,000 to 114,700,000, a change of 7,000,000 (6.5%).
- Net income of 17,400,000 contributed positively to equity growth.
- Dividend payments of 10,600,000 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $17.40 Million | +15.17% |
| Dividends Paid | $10.60 Million | -9.24% |
| Other Changes | $200.00K | +0.17% |
| Total Change | $- | 6.50% |
Book Value vs Market Value Analysis
This analysis compares Revenio Group Oyj's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.46x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 10.60x to 6.46x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $2.63 | $27.85 | x |
| 2021-12-31 | $2.95 | $27.85 | x |
| 2022-12-31 | $3.42 | $27.85 | x |
| 2023-12-31 | $3.76 | $27.85 | x |
| 2024-12-31 | $4.05 | $27.85 | x |
| 2025-12-31 | $4.31 | $27.85 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Revenio Group Oyj utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 15.17%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 15.86%
- • Asset Turnover: 0.73x
- • Equity Multiplier: 1.31x
- Recent ROE (15.17%) is below the historical average (19.44%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 19.17% | 21.88% | 0.53x | 1.64x | $6.39 Million |
| 2021 | 22.08% | 21.99% | 0.63x | 1.59x | $9.48 Million |
| 2022 | 23.93% | 22.43% | 0.71x | 1.50x | $12.66 Million |
| 2023 | 19.13% | 19.79% | 0.70x | 1.38x | $9.12 Million |
| 2024 | 17.18% | 17.87% | 0.73x | 1.31x | $7.73 Million |
| 2025 | 15.17% | 15.86% | 0.73x | 1.31x | $5.93 Million |
Industry Comparison
This section compares Revenio Group Oyj's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Revenio Group Oyj (REVXF) | $114.70 Million | 19.17% | 0.31x | $701.50 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |